Yahoo Finance • last year
DBV Technologies S.A. Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)... Full story
Yahoo Finance • 2 years ago
DBV Technologies S.A. Montrouge, France, March 7, 2023 DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old First patient screened at Midwest Allergy Sinus Asthm... Full story
Yahoo Finance • 2 years ago
DBV Technologies S.A. Montrouge, France, October 31, 2022 DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a... Full story
Yahoo Finance • 3 years ago
DBV Technologies S.A. AMF REGULATED INFORMATION Montrouge, France, July 27, 2022 Half-Year Report on the DBV Technologies Liquidity Contract with ODDOBHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT)... Full story
Yahoo Finance • 3 years ago
The biotech industry is volatile. Case in point: Axsome Therapeutics (NASDAQ: AXSM) and DBV Technologies (NASDAQ: DBVT) -- two small-cap biotechs -- recently saw their shares explode following positive developments. Here is the rundown on... Full story
Yahoo Finance • 3 years ago
DBV Technologies S.A. Montrouge, France, May 12, 2022 DBV Technologies Announces Results of Its 2022Ordinary and Extraordinary General Meeting Shareholders ApprovedAll Proposed Resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010... Full story
Yahoo Finance • 3 years ago
DBV Technologies S.A. Montrouge, France, May 2, 2022 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “Company”), a clin... Full story
Yahoo Finance • 3 years ago
Montrouge, France, May 2, 2022 DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results The U.S. Food and Drug Administration (FDA) has granted DBV Technologies a Type C meeting to align on the new V... Full story